A follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma.
A new radiopharmaceutical, I-131 metaiodobenzylguanidine (I-131 MIBG) was used to determine the location and to follow-up tumors in a 13-month-old girl with neuroblastoma. I-131 MIBG imaging revealed both a primary abdominal tumor and a distant metastatic orbital tumor. Follow-up study with I-131 MIBG imaging demonstrated significant resolution of tumors after external radiotherapy and chemotherapy. I-131 MIBG imaging is a simple, safe, and specific method of determining the location of tumors and also is clinically useful in the evaluation and management of patients with neuroblastoma.
D019797:3-Iodobenzylguanidine; D000008:Abdominal Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000556:secondary; D009918:Orbital Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D011877:Radionuclide Imaging; D013669:Technetium Tc 99m Medronate; D014057:Tomography, X-Ray Computed
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine; D013669:Technetium Tc 99m Medronate